guselkumab vs JNJ-78934804
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline
guselkumab · Tremfya
Marketed by Johnson & Johnson
QUASAR/GALAXI · Phase 3 · completed
Only IL-23i to beat ustekinumab head-to-head on endoscopy in a registrational trial — strong differentiator.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: February 2027 · NCT06260163 (registry estimate)
Reported efficacy
Percentage of Participants in Clinical Remission at Week 12: Percentage of Participants in Clinical Remission at Week 12 (Week 12): Placebo 6.5 Percentage of participants (95% CI 2.4 to 10.6) | Combined Guselkumab 400 mg 27.6 Percentage of participants (95% CI 22.4 to 32.8) (met)
Result source: NCT05528510
JNJ-78934804
Developed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2028 · NCT07577856 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | guselkumab | JNJ-78934804 |
|---|---|---|
| Clinical remission (induction) | 22.6% vs 7.9%+14.7 vs placeboNCT040334452 other results
| —Trial running · NCT07577856 |
| Clinical remission (maintenance) | 50% vs 18.9%+31.1 vs placeboNCT040334451 other result
| —Trial running · NCT07577856 |
| Clinical response (induction) | 61.4% vs 27.6%+33.8 vs placeboNCT040334453 other results
| —Trial running · NCT07577856 |
| Endoscopic improvement (induction) | —Trial running · NCT04033445 | —Trial running · NCT07577856 |
| Corticosteroid-free remission (maintenance) | —Trial running · NCT04033445 | —Trial running · NCT07577856 |
Clinical remission (induction)
- guselkumab
- 22.6% vs 7.9%+14.7 vs placeboNCT04033445
2 other results
- 21.1% vs 22.2% NCT03662542
- 36.6% vs 22.2% NCT03662542
- JNJ-78934804
- —Trial running · NCT07577856
Clinical remission (maintenance)
- guselkumab
- 50% vs 18.9%+31.1 vs placeboNCT04033445
1 other result
- 45.2% vs 18.9% NCT04033445
- JNJ-78934804
- —Trial running · NCT07577856
Clinical response (induction)
- guselkumab
- 61.4% vs 27.6%+33.8 vs placeboNCT04033445
3 other results
- 60.7% vs 27.6% NCT04033445
- 74.6% vs 61.1% NCT03662542
- 83.1% vs 61.1% NCT03662542
- JNJ-78934804
- —Trial running · NCT07577856
Endoscopic improvement (induction)
- guselkumab
- —Trial running · NCT04033445
- JNJ-78934804
- —Trial running · NCT07577856
Corticosteroid-free remission (maintenance)
- guselkumab
- —Trial running · NCT04033445
- JNJ-78934804
- —Trial running · NCT07577856
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
JNJ-78934804: no structured comparison results are available for Ulcerative Colitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. guselkumab: 4 of 4 rows · JNJ-78934804: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | guselkumab |
|---|---|
| Dropout rate | 2.8%200 mg IVa NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 show 17 more results—200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 4.1%200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC q4w to 200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —100 mg SC q8w to 200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —100 mg SC q8w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 0.9%400 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 0%Combination Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 1.4%Combination Phase: Guselkumab Mono NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Monotherapy Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Monotherapy Phase: Guselkumab Mono NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Safety Follow-up: Combination Ther NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Safety Follow-up: Guselkumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy |
| Discontinued due to AEs | 0.9%200 mg IVa NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 show 17 more results—200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 1.6%200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC q4w to 200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —100 mg SC q8w to 200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —100 mg SC q8w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 0%400 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 0%Combination Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 1.4%Combination Phase: Guselkumab Mono NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Monotherapy Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Monotherapy Phase: Guselkumab Mono NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Safety Follow-up: Combination Ther NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Safety Follow-up: Guselkumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy |
| Serious AEs | 0.9%200 mg IVa NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 show 17 more results3%200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 3.8%200 mg SC NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 3%200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 2.3%200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 2.3%200 mg SC NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 6.5%200 mg SC q4w to 200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 5.6%200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 6%200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 4.3%100 mg SC q8w to 200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 2.5%100 mg SC q8w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 2.7%400 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 1.4%Combination Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 2.8%Combination Phase: Guselkumab Mono NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy 4.2%Monotherapy Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 1.4%Monotherapy Phase: Guselkumab Mono NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy 0%Safety Follow-up: Combination Ther NCT03662542 · Phase 2 · registry result, not featured evidence · combination 3.1%Safety Follow-up: Guselkumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy |
| Most frequent reported AEs | 200 mg IVa anaemia 7.4% (placebo 10.2%) covid-19 5.6% (placebo 4.6%) abdominal pain 3.7% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 show 17 more results200 mg IV anaemia 6% (placebo 10.2%) upper respiratory tract infection 4.5% (placebo 0%) colitis ulcerative 3% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg SC colitis ulcerative 3.8% (placebo 2.8%) headache 3.8% (placebo 7.4%) anaemia 2.5% (placebo 10.2%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg IV anaemia 5% (placebo 10.2%) covid-19 5% (placebo 4.6%) headache 3% (placebo 7.4%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg IV covid-19 7.6% (placebo 4.6%) colitis ulcerative 4.1% (placebo 2.8%) nasopharyngitis 2.9% (placebo 1.9%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg SC covid-19 7% (placebo 4.6%) colitis ulcerative 5.4% (placebo 2.8%) anaemia 4.7% (placebo 10.2%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg SC q4w to 200 mg SC q4w colitis ulcerative 16.1% (placebo 2.8%) covid-19 6.5% (placebo 4.6%) abdominal pain 3.2% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg SC q4w covid-19 18.4% (placebo 4.6%) colitis ulcerative 16.8% (placebo 2.8%) pyrexia 6.4% (placebo 4.6%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg SC q4w colitis ulcerative 13.1% (placebo 2.8%) covid-19 10.1% (placebo 4.6%) arthralgia 8% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 100 mg SC q8w to 200 mg SC q4w covid-19 13% (placebo 4.6%) anaemia 8.7% (placebo 10.2%) colitis ulcerative 8.7% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 100 mg SC q8w covid-19 14.2% (placebo 4.6%) colitis ulcerative 10.2% (placebo 2.8%) arthralgia 6.1% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 400 mg IV anaemia 8.1% (placebo 10.2%) headache 5.4% (placebo 7.4%) arthralgia 3.6% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 anaemia 5.6% colitis ulcerative 5.6% headache 5.6% NCT03662542 · Phase 2 · registry result, not featured evidence · combination anaemia 8.5% upper respiratory tract infection 7% neutropenia 5.6% NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy colitis ulcerative 8.5% upper respiratory tract infection 8.5% headache 4.2% NCT03662542 · Phase 2 · registry result, not featured evidence · combination anaemia 8.6% headache 7.1% colitis ulcerative 5.7% NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy anaemia 0% colitis ulcerative 0% headache 0% NCT03662542 · Phase 2 · registry result, not featured evidence · combination anaemia 1.5% colitis ulcerative 1.5% headache 0% NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy |
Notes
- aPopulation comparability has not been reviewed for 6 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
guselkumab
show 3 more results
show 4 more results
Crohn's Disease
Shared mechanism: IL-23 p19 · full Crohn's Disease pipeline
guselkumab · Tremfya
Marketed by Johnson & Johnson
QUASAR/GALAXI · Phase 3 · completed
Only IL-23i to beat ustekinumab head-to-head on endoscopy in a registrational trial — strong differentiator.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: March 2027 · NCT05347095 (registry estimate)
Reported efficacy
superior to ustekinumab on pooled endoscopic endpoints (met)
Result source: QUASAR/GALAXI
JNJ-78934804
Developed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2028 · NCT07577843 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Crohn's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | guselkumab | JNJ-78934804 |
|---|---|---|
| Clinical remission (induction) | —Trial running · NCT03466411 | —Trial running · NCT07577843 |
| Endoscopic response (induction) | —Trial running · NCT03466411 | —Trial running · NCT07577843 |
| Clinical remission (maintenance) | —Trial running · NCT03466411 | —Trial running · NCT07577843 |
| Endoscopic response (maintenance) | —Trial running · NCT03466411 | —Trial running · NCT07577843 |
Clinical remission (induction)
- guselkumab
- —Trial running · NCT03466411
- JNJ-78934804
- —Trial running · NCT07577843
Endoscopic response (induction)
- guselkumab
- —Trial running · NCT03466411
- JNJ-78934804
- —Trial running · NCT07577843
Clinical remission (maintenance)
- guselkumab
- —Trial running · NCT03466411
- JNJ-78934804
- —Trial running · NCT07577843
Endoscopic response (maintenance)
- guselkumab
- —Trial running · NCT03466411
- JNJ-78934804
- —Trial running · NCT07577843
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
JNJ-78934804: no structured comparison results are available for Crohn's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. guselkumab: 3 of 4 rows · JNJ-78934804: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | guselkumab |
|---|---|
| Dropout rate | 12.3%200 mg IV q4w followed by 100 mg SC q8w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 show 7 more results2%200 mg IV q4w followed by 200 mg SC q4w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 5.4%200 mg IV q4w followed by 100 mg SC q8w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 8.6%200 mg IV q4w followed by 200 mg SC q4w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 11.5%200 mg IV q4w followed by 100 mg SC q8w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 20.5%1200 mg IV q4w followed by 200 mg SC q4w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 12.3%600 mg IV q4w followed by 200 mg SC q4w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 5.3%200 mg NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 |
| Discontinued due to AEs | —200 mg IV q4w followed by 100 mg SC q8w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 show 7 more results—200 mg IV q4w followed by 200 mg SC q4w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 —200 mg IV q4w followed by 100 mg SC q8w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 —200 mg IV q4w followed by 200 mg SC q4w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 —200 mg IV q4w followed by 100 mg SC q8w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 —1200 mg IV q4w followed by 200 mg SC q4w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 —600 mg IV q4w followed by 200 mg SC q4w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 —200 mg NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 |
| Serious AEs | 8.2%200 mg IV q4w followed by 100 mg SC q8w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 show 7 more results4.1%200 mg IV q4w followed by 200 mg SC q4w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 12.8%200 mg IV q4w followed by 100 mg SC q8w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 9.9%200 mg IV q4w followed by 200 mg SC q4w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 8.8%200 mg IV q4w followed by 100 mg SC q8w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 6.8%1200 mg IV q4w followed by 200 mg SC q4w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 6.8%600 mg IV q4w followed by 200 mg SC q4w NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 7.9%200 mg NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 |
| Most frequent reported AEs | 200 mg IV q4w followed by 100 mg SC q8w arthralgia 11% (placebo 7%) nasopharyngitis 11% (placebo 9.3%) crohn's disease 8.2% (placebo 11.6%) NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 show 7 more results200 mg IV q4w followed by 200 mg SC q4w covid-19 14.9% (placebo 0%) headache 10.8% (placebo 9.3%) arthralgia 9.5% (placebo 7%) NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 200 mg IV q4w followed by 100 mg SC q8w covid-19 12.2% (placebo 0%) upper respiratory tract infection 10.1% (placebo 4.7%) arthralgia 9.5% (placebo 7%) NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 200 mg IV q4w followed by 200 mg SC q4w covid-19 20.5% (placebo 0%) upper respiratory tract infection 8.6% (placebo 4.7%) arthralgia 7.3% (placebo 7%) NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 200 mg IV q4w followed by 100 mg SC q8w covid-19 18.2% (placebo 0%) upper respiratory tract infection 9.5% (placebo 4.7%) crohn's disease 6.8% (placebo 11.6%) NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 1200 mg IV q4w followed by 200 mg SC q4w nasopharyngitis 11% (placebo 9.3%) headache 9.6% (placebo 9.3%) arthralgia 5.5% (placebo 7%) NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 600 mg IV q4w followed by 200 mg SC q4w headache 13.7% (placebo 9.3%) nasopharyngitis 12.3% (placebo 9.3%) anaemia 8.2% (placebo 2.3%) NCT03466411 · Phase 3 · Crohn's Disease · phase 2/3 200 mg pyrexia 39.5% headache 15.8% nasopharyngitis 10.5% NCT04397263 · Phase 3 · monotherapy · Crohn's Disease · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
guselkumab
show 2 more results
show 3 more results
show 3 more results
show 11 more results
show 11 more results
show 11 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: guselkumab's landscape · JNJ-78934804's landscape